PRIME: Panitumumab Randomized Trial In Combination with Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy

- Man or woman at least 18 years old - Diagnosis of metastatic colorectal cancer - At least 1 uni-dimensionally measurable lesion of at least 20 mm per modified RECIST - Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 - Paraffin-embedded tumor tissue from the primary tumor or metastasis available for central analyse

- History or known presence of central nervous system (CNS) metastases - History of another primary cancer, except: Curatively treated in situ cervical cancer, or Curatively resected non-melanoma skin cancer, or Other primary solid tumor curatively treated with no known active disease present and no treatment administered for ≥ 5 years before randomization - Prior chemotherapy or systemic therapy for the treatment of metastatic colorectal carcinoma except: adjuvant fluoropyrimidine-based chemotherapy or prior fluoropyrimidine therapy administered solely for the purpose of radiosensitization - Prior oxaliplatin therapy - Prior anti-epidermal growth factor receptor (EGFr) antibody therapy (eg, cetuximab) or treatment with small molecule EGFr inhibitors (eg, erlotinib) - Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) 1 year prior to randomization History of interstitial lung disease (eg, pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest computed tomography (CT) scan - Active inflammatory bowel disease or other bowel disease causing chronic diarrhea (defined as > Common terminology criteria (CTC) grade 2 [CTCAE version 3.0]) - Peripheral sensory neuropathy with functional impairment